It also suppressed MMPs in metastatic ovarian cancer: treatment (50 μM, 75 μM) inhibited the gene expression, protein expression, and proteolytic activity of MMP-2 and MMP-9, thus attenuating the metastatic potential of ovarian cancer cells [93]. This evidence concerns the gene MMP9 and ovarian carcinoma.